FDA grants priority review for Zealand Pharma’s dasiglucagon
The US FDA has granted priority review for Zealand Pharma’s dasiglucagon for hypoglycemia in the infants with congenital hyperinsulinism.
The US FDA has granted priority review for Zealand Pharma’s dasiglucagon for hypoglycemia in the infants with congenital hyperinsulinism.
What's Your Reaction?
